RPI ID: 2014-043-601

Innovation Summary:
This invention introduces a set of novel anti-microbial peptides effective against M. tuberculosis and streptococcus species. The peptides were developed using a computational design strategy to enhance biological activity and specificity while minimizing toxicity to human cells. The design methodology allows researchers to screen and optimize peptide candidates in silico before laboratory synthesis. By targeting specific bacterial mechanisms, these peptides demonstrate potent inhibitory effects. In addition to providing therapeutic candidates, the invention outlines a repeatable process for generating future antimicrobial compounds. The technology offers a scalable platform for rapid drug development to combat antibiotic-resistant pathogens.

Challenges / Opportunities:
The rise of drug-resistant bacteria poses a major public health challenge. Conventional antibiotics are increasingly ineffective against strains like multidrug-resistant tuberculosis. There is a pressing need for novel antimicrobial agents that function via different mechanisms. This invention meets that need by providing peptides with new modes of action and a rational design framework for producing them. It offers opportunities for application in clinical treatments, diagnostics, and even coatings for antimicrobial surfaces.

Key Benefits / Advantages:
✔ Potent activity against TB and streptococcus
✔ Rational design reduces development time
✔ Low toxicity to host cells

Applications:
• Tuberculosis therapeutics
• Peptide-based antimicrobials
• Antimicrobial coatings and diagnostics

Keywords:
#antimicrobial #peptidedesign #drugresistance #tuberculosis

Intellectual Property:
US Issued Patent 10,336,790 B2